Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Summary

This research study is studying the effects of adding a certain type of immunotherapy to standard bladder-directed radiation as a treatment for muscle-invasive urothelial carcinoma of the bladder. The drug in this study is: Avelumab (also known as BAVENCIO®)

Timeline

Start

2018-12-13

Primary completion

2025-02-24

Completion

2025-02-24

Outcome

Outcome not reported

Stopped (Enrollment): “In agreement with the drug sponsor and the institution, the trial has been terminated due to slow accrual.”

Drugs

Indications